Nomura: Lowers BUD APAC (01876) target price to HK$7.8, maintains "Buy" rating.
The bank expects BUD APAC's third-quarter revenue and normalized EBITDA to decline by 9% and 20% year-on-year respectively, and as no turnaround is in sight in the short term, its weak sales and EBITDA growth trend is expected to continue into the fourth quarter.
Nomura released a research report stating that it expects BUD APAC (01876) to record another weak performance in the third quarter, with continued weakening in the China market and mediocre growth momentum in the South Korea market, partly offset by sustained rapid growth in the India market; it lowered the company's target price from HK$8.6 to HK$7.8, maintaining a "Buy" rating, and believes the current valuation is not expensive.
The bank expects BUD APAC's third-quarter revenue and normalized EBITDA to decline by 9% and 20% year-on-year respectively, and as no turnaround is seen in the short term, its trend of sluggish sales and EBITDA growth is expected to continue into the fourth quarter.
Related Articles
.png)
HK Stock Market Move | GCL TECH (03800) rose over 5% in late trading. GCL's 400,000-ton lithium iron phosphate project breaks ground, transforming into a global multi-product new energy materials platform.

Eli Lilly (LLY.US) triple agonist announces Phase III data

HK Stock Market Move | MARKETINGFORCE (02556) rose over 8% in late trading; recent fundraising to ramp up computing infrastructure; share of Token-related revenue continues to rise.
HK Stock Market Move | GCL TECH (03800) rose over 5% in late trading. GCL's 400,000-ton lithium iron phosphate project breaks ground, transforming into a global multi-product new energy materials platform.
.png)
Eli Lilly (LLY.US) triple agonist announces Phase III data

HK Stock Market Move | MARKETINGFORCE (02556) rose over 8% in late trading; recent fundraising to ramp up computing infrastructure; share of Token-related revenue continues to rise.






